Wellington Partners

What they fund

• Stage: Early- and growth-stage life science companies [1].
• Sector: Therapeutics, Medical Devices, Diagnostics, Digital Health, and Industrial Biotechnology [1].
• Geography: Germany, Europe and beyond [1].
• Company Profile: Companies with strong IP protection and solid proofs of concept, aiming for high performers with significant upside potential [2].
• Deal Size: The firm's fifth fund is EUR 210m, more than double its predecessor, allowing it to back growth ambitions [1].

Investment thesis

Wellington Partners is a leading European venture capital firm investing in early- and growth-stage life science companies from Germany, Europe and beyond, with breakthrough and truly innovative technologies [1]. The firm employs a 'thinking bigger' approach, enabling entrepreneurial vision through a highly experienced team, a strong track record, and a strongly diversified portfolio to unlock potential [1]. They focus on companies with strong IP protection and solid proofs of concept, aiming for high performers with significant upside potential [2]. The firm supports entrepreneurs in sectors such as Therapeutics, Medical Devices, Diagnostics, Digital Health, and Industrial Biotechnology, helping them turn ideas into reality and become global leaders [1].

Credibility: The firm's homepage explicitly states its mission and strategic approach [1]. The Wikipedia entry confirms the firm's focus on life sciences and technology, noting its history of closing funds in these sectors [2].

Value add

Wellington Partners provides a highly experienced team and a strong track record to help entrepreneurs turn ideas into reality [1]. The firm has a strongly diversified portfolio, which helps to unlock potential [1]. The firm's team includes partners and venture advisors with deep expertise in life sciences [1].

Fit verdict: Wellington Partners is a strong fit for life science companies in Germany and Europe seeking growth-stage funding and strategic support.

Founder diligence script:

• What is the firm's typical follow-on investment strategy for portfolio companies?
• How does the firm leverage its network to help portfolio companies with regulatory approvals?
• What is the firm's approach to board involvement and strategic guidance?
• How does the firm measure success for its portfolio companies?
• What is the firm's track record of successful exits in the life science sector?

Portfolio focus

• Nuclidium: Copper-based radiopharmaceutical platform, recently closed a Series B extension [1].
• Confo Therapeutics: Drug discovery platform for high value GPCR targets, initiated Phase 2 clinical trials [1].
• Polares Medical: Advanced U.S. expansion of MRace following strong clinical results, raised $50 Million Series C [1].
• Beren Therapeutics: Developed Adrabetadex for Infantile-Onset Niemann Pick Disease Type C, received FDA acceptance of NDA [1].
• Seamless Therapeutics: Developing programmable recombinase-based therapeutics for hearing loss, announced global collaboration with Lilly [1].

Notable investments & exits

• ImCheck Therapeutics: Acquired by Ipsen in October 2025, expanding its leadership in oncology [1].
• Spotify: Wellington Partners invested in Spotify prior to July 10, 2009, taking a 3.8% stake for €6.5 million [3].

Strategic implications

Wellington Partners' focus on life sciences and its strong track record make it a key player in the European life science VC landscape. Its large fifth fund suggests a continued commitment to the sector. The firm's emphasis on strong IP protection and solid proofs of concept indicates a preference for de-risked investments, which may limit its exposure to early-stage, high-risk ventures. The firm's co-investment with Lilly suggests a strong network in the pharmaceutical industry, which could be a significant advantage for portfolio companies seeking regulatory approvals and commercial partnerships.

Where they could go further

Wellington Partners could expand its focus to include more early-stage life science companies to capture higher-growth potential. The firm could enhance its value-add by providing more operational support to portfolio companies, particularly in areas such as regulatory strategy and commercialization. Wellington Partners could explore co-investment opportunities with other life science VCs to diversify its portfolio and reduce risk. The firm could improve its transparency by providing more detailed information about its fund performance and exit track record.